范钰+++钱震++苏勤军++李甜甜++刘斌

    [摘要] 免疫治疗作为最热门的研究领域之一，诸多临床研究中心在肿瘤药物试验中证实其疗效显著。程序性死亡配体1(PD-L1)是一种参与免疫抑制通路的分子，在较多实体肿瘤细胞及其周围T淋巴细胞表面表达显著，能与其程序性死亡受体1(PD-1)结合，抑制肿瘤组织周围的免疫微环境，促进肿瘤细胞的恶化。三阴性乳腺癌(TNBC)，作为乳腺癌的一种亚型，对目前乳腺癌治疗手段均不敏感，患者预后及生活质量较差。本文通过对TNBC中PD-1/PD-L1的表达及相关抑制药物临床试验的疗效进展进行阐述，为制订TNBC患者的个体化治疗方案提供新思路。

    [关键词] 程序性死亡受体1；程序性死亡配体1；三阴性乳腺癌；进展

    [中图分类号] R737.9 [文献标识码] A [文章编号] 1673-7210(2017)11(c)-0051-05

    Advances in the study of PD-1/PD-L1 in triple-negative breast cancer

    FAN Yu QIAN Zhen SU Qinjun LI Tiantian LIU Bin

    Department of Pathology， Lanzhou General Hospital of Lanzhou City， Gansu Province， Lanzhou 730050， China

    [Abstract] Immunotherapy is one of the most popular research fields， and has proved to be effective by many clinical research centers in tumor drug trials. Program-med death receptor ligand 1 (PD-L1) is a molecule involved in immunosuppression pathway， and express in more solid tumor cells and the peripheral T lymphocyte significantly on the surface. It can combine with the programmed death receptor 1 (PD-1)， inhibit the immune micro-environment around the tumor tissue ......